Prevalence of renal dysfunction in tacrolimus‐treated pediatric transplant recipients: A systematic review

Abstract

Renal dysfunction after non-renal transplantation in adult tacrolimus-treated transplant patients is well documented. Little is known about its prevalence in children. Age-related changes in both disposition and effect of tacrolimus as well as renal function may preclude extrapolation of adult data to children. To systematically review the literature on renal dysfunction in non-renal pediatric transplant recipients treated with tacrolimus. PubMed/Medline, Embase, and Google were searched from their inception until April 19, 2012, with the search terms "tacrolimus," "renal function," "transplantation," and "children." Eighteen of 385 retrieved papers were considered relevant. Twelve dealt with liver, four with heart transplant, one with heart and lung transplant, and one with intestinal recipients. Reported prevalences of mild and severe chronic kidney disease ranged from 0% to 39% and 0% to 71.4%, respectively, for liver, and from 22.7% to 40% and 6.8% to 46%, respectively, for heart and/or lung transplant recipients. Ranges remained wide after adjusting for follow-up time and disease severity. Possible explanations are inclusion bias and definitions used for renal dysfunction. A considerable proportion of pediatric non-renal transplant patients who receive tacrolimus-based immunosuppression, appear to suffer from chronic kidney disease. This conclusion warrants further research into the real risk, its risk factors, and individualization of immunosuppressant therapy.

Early and Late Complications After Liver Transplantation for Propionic Acidemia in Children: A Two Centers Study

“…The use of calcineurin inhibitors is certainly partially responsible, with a prevalence of renal dysfunction estimated between 2-17% 5 years after LT in children (18)(19)(20). On the other hand, most MMA patients (where the defective enzyme resides in the same pathway) develop progressive renal failure by adolescence or early adulthood (5).…”

Pediatric Perspective on Pharmacogenomics

“…Studies related to tacrolimus treatment in pediatric kidney transplant patients have helped to identify factors that explain treatment variability and determine dosage regimens [110][111][112][113]. The oral clearance was found to be significantly related to body weight and was greater in patients with low hematocrit levels and lower in patients with a CYP3A5 polymorphism.…”

Practice recommendations: A new type of article in Pediatric Transplantation

“… raised awareness about a high prevalence of chronic kidney disease (CKD) in all non‐renal solid organ transplant recipients, with CKD being a major cause of morbidity and mortality after non‐renal transplantation . The same concerns apply for pediatric heart transplantation , liver transplantation , with the highest prevalence appearing in lung transplantation recipients , and small bowel transplantation . Clearly, monitoring of renal function is important.…”